ClinicalTrials.gov
ClinicalTrials.gov Menu

Breast Cancer Risk Reduction: A Patient Doctor Intervention (BreastCARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01830933
Recruitment Status : Completed
First Posted : April 12, 2013
Results First Posted : May 16, 2013
Last Update Posted : August 19, 2014
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
California Breast Cancer Research Program
Information provided by (Responsible Party):
University of California, San Francisco

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Participant);   Primary Purpose: Prevention
Condition: Breast Cancer
Intervention: Other: BreastCARE

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Usual Care Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care.
BreastCARE Intervention

Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk.

Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patients before she meets with her doctor.

BreastCARE : The physician will receive a physician report that contains information similar to the patient report.

Participant Flow:   Overall Study
    Usual Care   BreastCARE Intervention
STARTED   823   812 
Completed Meet-up   675   603 
COMPLETED   655   580 
NOT COMPLETED   168   232 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Number of participants who completed follow-up.

Reporting Groups
  Description
Usual Care Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care.
BreastCARE Intervention

Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk.

Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patients before she meets with her doctor.

BreastCARE : The physician will receive a physician report that contains information similar to the patient report.
Total Total of all reporting groups

Baseline Measures
   Usual Care   BreastCARE Intervention   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 655   580   1235 
Age, Customized 
[Units: Participants]
 		     
<50 years   183   182   365 
51-65 years   362   300   662 
>65 years   110   98   208 
Gender 
[Units: Participants]
 		     
Female   655   580   1235 
Male   0   0   0 
Race/Ethnicity, Customized 
[Units: Participants]
 		     
Non-Latina White   229   202   431 
Latina   144   141   285 
Black/ African American   150   125   275 
Asian or Pacific Islander   123   105   228 
Native American or Other   9   7   16 
Region of Enrollment 
[Units: Participants]
 		     
United States   655   580   1235 


  Outcome Measures

1.  Primary:   Knowledge of Breast Cancer Risk Factors   [ Time Frame: one week post-initial visit (approximately one week) ]
  Show Outcome Measure 1

2.  Primary:   Percentage of Participants With Correct Perception of Risk   [ Time Frame: baseline, one week post-initial visit (approximately one week) ]
  Show Outcome Measure 2

3.  Primary:   Percentage of Participants Who Had a Discussion of Breast Cancer Risk   [ Time Frame: one week post-initial visit (approximately one week) ]
  Show Outcome Measure 3

4.  Primary:   Percentage of Participants Who Reported Discussion of Mammography Screening   [ Time Frame: up to 14 months ]
  Show Outcome Measure 4


  Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
Usual Care Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care.
BreastCARE Intervention

Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk.

Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patients before she meets with her doctor.

BreastCARE : The physician will receive a physician report that contains information similar to the patient report.

Serious Adverse Events
    Usual Care   BreastCARE Intervention
Total, Serious Adverse Events     
# participants affected / at risk   0/655 (0.00%)   0/580 (0.00%) 




  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Celia P. Kaplan, Professor
Organization: University of California, San Francisco
phone: 415-502-5601
e-mail: celia.kaplan@ucsf.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01830933     History of Changes
Obsolete Identifiers: NCT01836250
Other Study ID Numbers: 150B-0158
First Submitted: April 10, 2013
First Posted: April 12, 2013
Results First Submitted: May 15, 2013
Results First Posted: May 16, 2013
Last Update Posted: August 19, 2014